Levofloxacin
| Code | Size | Price |
|---|
| TAR-T6567-100mg | 100mg | £109.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T6567-1mL | 1 mL * 10 mM (in DMSO) | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Levofloxacin is a broad-spectrum antibiotic topoisomerase II and topoisomerase IV inhibitor, used to treat respiratory, urinary tract, gastrointestinal, and abdominal infections.
CAS:
100986-85-4
Formula:
C18H20FN3O4
Molecular Weight:
361.37
Pathway:
Microbiology/Virology; DNA Damage/DNA Repair
Purity:
0.9831
SMILES:
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O
Target:
Topoisomerase; Antibacterial; Antibiotic
References
Kong Y, Geng Z, Jiang G, et al.Comparison of the in vitro antibacterial activity of ofloxacin, levofloxacin, moxifloxacin, sitafloxacin, finafloxacin, and delafloxacin against Mycobacterium tuberculosis strains isolated in China.Heliyon.2023
Kato M, et al. Antimicrob Agents Chemother,1995, 39(9), 1979-1983.
Davis R, et al. Drugs,1994, 47(4), 677-700.
Shen X, Zhang W, Peng C, et al. In vitro anti?bacterial activity and network pharmacology analysis of Sanguisorba officinalis L. against Helicobacter pylori infection. Chinese medicine. 2021, 16(1): 1-19.
Fu KP, et al. Antimicrob Agents Chemother,1992, 36(4), 860-866.
Shen X, Zhang W, Peng C, et al. In vitro anti?bacterial activity and network pharmacology analysis of Sanguisorba officinalis L. against Helicobacter pylori infection[J]. Chinese medicine. 2021, 16(1): 1-19.
Mor N, et al. Antimicrob Agents Chemother,1994, 38(5), 1161-1164.
Holtom PD, et al. J Orthop Res,2000, 18(5), 721-727.
Yan J, Peng C, Chen P, et al. In-vitro anti-Helicobacter pylori activity and preliminary mechanism of action of Canarium album raeusch. Fruit extracts. Journal of Ethnopharmacology. 2021: 114578.